GLP-1semaglutidesglt2 inhibitorsfinerenonediabetic kidney diseaseflow trial

Network meta-analysis ranks SGLT2 inhibitors above semaglutide in diabetic kidney disease

Across six trial datasets and 20,521 patients, semaglutide cut kidney events by 24 percent, trailing SGLT2 inhibitors and ahead of finerenone.

By Maren Holt · Senior Reporter, GLP-1

Sep 23 20:00 ETSource: Frontiers in pharmacology

The wire

01The Bayesian analysis in Frontiers in Pharmacology found kidney-outcome hazard ratios of 0.70 for SGLT2 inhibitors, 0.76 for semaglutide and 0.84 for finerenone, with SUCRA values of 94.5, 68.0 and 37.5 percent.
02Clinicians layering cardiorenal therapy on RAS blockade now have a comparative hierarchy that places semaglutide, built on the FLOW trial, second rather than first.
03Comparisons are indirect, and the authors say the SGLT2-versus-finerenone result depends on separating FIDELIO-DKD and FIGARO-DKD and should be treated as hypothesis-generating.

From the source

SGLT2 inhibitors, semaglutide, and finerenone in diabetic kidney disease: a Bayesian network meta-analysis
Frontiers in pharmacology · 2026 · He Z, Wang X, Zhang L et al.

Read at pubmed.ncbi.nlm.nih.gov

Source URL https://pubmed.ncbi.nlm.nih.gov/42851802/